Investment in R&D for the quarter has been posted at Rs 3,546 million
In Q3 FY2022, the gross profit was Rs 23,929 million compared to Rs 23,769 million in Q2 FY2022, with a margin of 58.5 per cent. The personnel cost was 18.2 per cent of sales at Rs 7,438 million compared to Rs 7,586 million in Q2 FY2022. Manufacturing and other expenses were 33.1 per cent of sales at Rs 13,518 million compared to Rs 11,425 million in
Q2 FY2022. Investment in R&D for the quarter was Rs 3,546 million (8.7 per cent of sales).
India formulation sales for Q3 FY2022 were INR 14,733 mn, down 4.5 per cent as compared to INR 15,435 mn in Q2 FY2022, up 7.8 per cent as compared to Rs 13,669 million in Q3 FY2021; accounting for 36 per cent of Lupin’s global sales. India Region Formulations sales grew by 11.9 per cent in the quarter as compared to Q3 FY2021. The company launched one brand in the Respiratory segment and two brands in the cardiac segment in the quarter.
Nilesh Gupta, MD, Lupin said, “We are on the path of sustained growth across markets. Our inhalation portfolio continues to build share in the U.S. and helped register double-digit growth sequentially, despite pricing and demand challenges on seasonal products. The inflationary environment has impacted margins, but we remain focussed on margin and EBIDTA improvement as we deliver on key product launches, cost optimization and improving efficiencies, especially by H2 FY23.”
